Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 18,892 | 17,795 | 23,585 | 20,317 | 19,479 |
| Gross Profit | 18,892 | 17,795 | 23,585 | 20,317 | 19,479 |
| Operating Expenses | 55,605 | 57,246 | 53,598 | 47,365 | 52,019 |
| Operating Income | -36,713 | -39,451 | -30,013 | -27,048 | -32,540 |
| Interest Expense | 1,997 | 0 | 0 | 0 | 0 |
| Other Income | 3,866 | 1,837 | 993 | 750 | 393 |
| Pre-tax Income | -34,844 | -37,614 | -29,020 | -26,298 | -32,147 |
| Income Tax | 4,221 | 44 | -34 | 50 | -447 |
| Net Income Continuous | -39,065 | -37,658 | -28,986 | -26,348 | -31,700 |
| Net Income | $-39,065 | $-37,658 | $-28,986 | $-26,348 | $-31,700 |
| EPS Basic Total Ops | -1.86 | -1.79 | -1.39 | -1.27 | -1.53 |
| EPS Basic Continuous Ops | -1.86 | -1.79 | -1.39 | -1.27 | -1.53 |
| EPS Diluted Total Ops | -1.86 | -1.79 | -1.39 | -1.27 | -1.53 |
| EPS Diluted Continuous Ops | -1.86 | -1.79 | -1.39 | -1.27 | -1.53 |
| EBITDA(a) | $-37,509 | $-39,917 | $-29,841 | $-26,340 | $-31,634 |